Blog

$Katy Rezvani: The Phase I trial of AFM13-precomplexed cord blood NK cells in relapsed/refractory CD30+ lymphomas$

Katy Rezvani/mdanderson.org

Apr 5, 2025, 14:14

Katy Rezvani: The Phase I trial of AFM13-precomplexed cord blood NK cells in relapsed/refractory CD30+ lymphomas

Katy Rezvani, Sally Cooper Murray Chair in Cancer Research at MD Anderson Cancer Center, shared a post on LinkedIn:

“Please check out our paper published in Nature Medicine on the Phase I trial of AFM13-precomplexed cord blood NK cells in relapsed/refractory CD30+ lymphomas.

Led by Dr. Yago Nieto and an outstanding team of co-authors and collaborators, this study marks the first clinical demonstration of NK cell redirection using a bispecific engager. We report an ORR of 92.9% and CR of 66.7% in 42 patients with a median of 7 prior therapies and show that this approach is safe and may serve as a bridge to SCT.

Excited to move forward with our next generation engineered NK cells in combination with engagers and mAbs!”

cancer fight against cancer Global fight against cancer Katy Rezvani lymphomas MD Anderson Cancer Center Nature Medicine NK cells OncoDaily Oncology Yago Nieto

OncoBillionaires of 2025: The Titans Behind the Cancer Revolution

Fellows of ASCO (FASCO) Recipients For Last Quarter

Val Kilmer Dies at 65: The Actor Who Fought Throat Cancer and Inspired Generations

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

Highlights from ELCC 2025